GlassScriptPhysician profile
Darin K Stockton
NPI 1689638652
$7,421.75
in general payments reported to CMS, 2019-2025
49 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what 87% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $988 · 2020: $724 · 2021: $1,257 · 2022: $1,284 · 2023: $1,117 · 2024: $845 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,089 · Education: $79.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,088.96 |
| Education | $79.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $850.90 | 2019-2025 | Linzess, Synthroid, Ubrelvy |
| Glaxosmithkline, LLC. | $820.29 | 2019-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Pfizer INC. | $628.71 | 2019-2025 | |
| Novo Nordisk INC | $597.62 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $426.43 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $416.34 | 2019-2025 | Jardiance |
| Amgen INC. | $311.78 | 2019-2025 | Otezla, Repatha, Repatha |
| Astellas Pharma US INC | $311.12 | 2019-2025 | Veozah, Myrbetriq |
| Amarin Pharma, INC. | $310.21 | 2019-2021 | |
| Abbott Laboratories | $248.67 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $241.32 | 2019-2025 | Mounjaro, Zepbound, Kisunla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $217.07 | 2020-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $215.98 | 2023-2025 | Gemtesa |
| Novartis Pharmaceuticals Corporation | $168.72 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $157.92 | 2020-2023 | Belsomra, Steglatro |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darin Stockton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.